Home » PEGASUS BIOLOGICS RECEIVES FDA APPROVAL TO MARKET ORTHADAPT BIOIMPLANTS
PEGASUS BIOLOGICS RECEIVES FDA APPROVAL TO MARKET ORTHADAPT BIOIMPLANTS
Pegasus Biologics, Inc. developers of novel bioimplants using proprietary technologies announced that the FDA has granted a 510K for the OrthADAPT(TM) Bioimplant, an intelligent, adaptable biologic scaffold which fortifies and promotes tissue remodeling while retaining long-term strength. This grants Pegasus Biologics clearance to market its bioimplants to reinforce compromised soft tissues in sports medicine, orthopedic, and spine applications.
Yahoo News (http://biz.yahoo.com/bw/050816/165361.html?.v=1)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May